deltatrials

Overactive bladder Trials in Toronto, Canada

Conditions / Overactive bladder / Toronto, Canada

Overactive bladder is a medical condition with active clinical research programs worldwide.

18 total trials for this combination

Showing top 10 of 18 trials

Trials

NCT ID Title Status Phase
NCT01972841 This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder COMPLETED PHASE3
NCT03492281 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) COMPLETED PHASE3
NCT02660138 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 TERMINATED PHASE3
NCT02045862 A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder COMPLETED PHASE3
NCT01302067 A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine COMPLETED PHASE4
NCT03902080 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) COMPLETED PHASE3
NCT02757768 A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) COMPLETED PHASE4
NCT00444925 Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) COMPLETED PHASE3
NCT02386072 A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) COMPLETED —
NCT01093534 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. COMPLETED PHASE4

Related Pages